Mason Marks, a visiting fellow at Yale Law School’s Information Society Project, argues in an opinion at the Washington Post (12/20) for strong oversight of emerging suicide prediction tools used commercially by companies such as Facebook. Marks writes that “corporations outside health care are racing to use AI to predict suicide in billions of consumers, and they treat their methods as proprietary trade secrets. These private-sector efforts are completely unregulated,” but he says the FDA “could exercise its power to regulate medical products and treat suicide prediction tools like mobile health apps or software-based medical devices.”
Related Links:
— “Suicide prediction technology is revolutionary. It badly needs oversight, “Mason Marks, The Washington Post, December 21 2018.